Putnam Associates Case Interview: Prep Guide and Worked Example
Preparing for a Putnam Associates case interview means practicing how to lead a structured, hypothesis-driven conversation around biopharma commercial strategy. As BCG's case interview preparation guide explains, a consulting case presents a realistic business challenge where you structure your approach, ask thoughtful questions, analyze data, perform quick calculations, and identify the most important factors. Rather than reciting standard frameworks, you drive the analysis step by step with pen and paper and end with a number-backed recommendation.
Updated
How consulting interviews are structured from application to final round
Across strategy consulting firms, hiring for client-facing roles follows a clear sequence that tests both analytical rigor and interpersonal fit. BCG's interview process page outlines four core stages for client-facing consulting roles: an initial application, a skills interview exploring your resume and motivation, a case interview assessing problem-solving and analytical skills, and a team interview evaluating communication and problem-solving.
Whether you apply from an undergraduate program or an advanced degree track, expect your interviews to blend two evaluation types. You will face behavioral fit questions about your past experiences alongside live case interviews where you solve a commercial problem out loud.
If you are interviewing virtually, set up your room early. McKinsey's interviewing guide advises choosing a quiet, private space, keeping a laptop charger, pen, paper, and water within reach, keeping your camera on with virtual backgrounds or blurring disabled, and turning off installed AI note-taking software or virtual assistants. Calculators are not allowed during live case interviews, so write your arithmetic neatly on scratch paper and talk your interviewer through each step. Practice a case free, no sign-up, to test your structuring speed before your first round.
Core consulting interview components and how to prepare
| Component | What it assesses | Official guidance on how to handle it |
|---|---|---|
| Application and resume screen | Written communication and relevant accomplishments | Provide accurate, thorough information and make distinctive accomplishments easy to spot |
| Skills and personal experience interview | Motivation, collaboration, and past actions under pressure | Discuss real experiences in detail, focus on your specific role, and lead with reasoning rather than rehearsed scripts |
| Live case interview | Problem-solving, logical structure, data analysis, and quick calculations | Structure your approach, ask thoughtful questions, clarify assumptions, and share problem-specific solutions instead of standard frameworks |
| Written or online case assessment (where used) | Business judgment, logical reasoning, and quantitative aptitude under time limits | Read exhibits carefully, track units, and check whether data supports each conclusion before moving on |
How to drive a candidate-led life sciences case
In a candidate-led case interview, nobody hands you a pre-made checklist of questions. You receive a realistic business challenge and work through it step by step. What matters most is how you approach the problem and the quality of your reasoning, because there is not always a single right answer.
Listen carefully to the client's exact objective and build solutions specific to the asset rather than forcing standard frameworks onto the prompt. Dropping a generic revenue-minus-cost tree onto a biotechnology question misses what drives value in life sciences, such as clinical differentiation, manufacturing yield, regulatory approval, and payer access.
Use five clear moves to steer any biopharma case from the opening prompt to your final recommendation:
- Clarify the clinical and commercial goal. Ask two or three sharp questions to pin down the disease area, the stage of clinical development, the geography, and the financial or strategic hurdle the client cares about.
- Build a custom structure. Take a quiet moment to organize three or four non-overlapping branches built specifically for this drug or device, state them out loud, and propose which branch to test first and why.
- Propose next steps proactively. Instead of asking the interviewer what to do next, state your hypothesis and request the exact data needed to test it, such as eligible patient counts, clinical trial endpoints, or payer rebate levels.
- Talk through your math with units. Label every number, whether patients, vials, infusions, or dollars, so you never confuse percentages with absolute figures, and sense-check your result out loud.
- End with an answer-first recommendation. State your decision in the first sentence, back it with the key number from your math, name the biggest clinical or commercial risk, and propose the immediate next step.
Life sciences concepts and case types you should know
You do not need a medical degree to pass a life sciences consulting case interview, even if you come from a liberal arts, engineering, or business background. Consulting firms seek problem-solvers from a wide range of disciplines, and critical thinking is what matters most. Still, knowing core biopharma concepts keeps you calm when a prompt introduces clinical endpoints or patent cliffs.
Review these building blocks and case archetypes before your interviews:
- Clinical development and endpoints: Drug candidates progress from preclinical lab testing into early human safety and dosing trials, mid-stage efficacy studies, and late-stage registration trials reviewed by regulators. Distinguish efficacy measures (such as survival or tumor response) from safety and tolerability profiles.
- Indication and line of therapy: Therapies are approved for specific diseases and defined patient groups. Check whether the drug targets newly diagnosed first-line patients, later-line relapsed or refractory patients who failed prior treatments, or a subgroup identified by a diagnostic biomarker.
- Manufacturing and supply chain: Small-molecule pills generally cost little per dose to produce at scale. Complex biologics and autologous cell therapies require specialized facilities, strict batch release testing, and cold-chain logistics that directly affect unit margins.
- Commercial product launch and go-to-market cases: When asked how to launch a new therapy, group your structure into four pillars: physician segmentation (identifying high-volume specialists), sales force and medical affairs sizing, payer coverage and specialty pharmacy distribution, and patient adherence or financial support programs.
- Loss of exclusivity (LOE) and lifecycle management cases: When a branded drug nears patent expiration and faces generic or biosimilar entry, test defense levers across timing and segments. Common levers include launching an extended-release or subcutaneous formulation, expanding into new disease indications, adjusting payer rebate contracts, or introducing an authorized generic.
Drug pricing and market access frameworks
In consumer goods cases, the customer who chooses the product also pays for it. In biopharma cases, physicians prescribe, patients take the therapy, and third-party payers or health systems reimburse the bill. Because of that split, pricing and market access prompts appear frequently in life sciences interviews.
When you structure a drug pricing or reimbursement question, start by separating how the manufacturer sets a benchmark price from how payers control patient access:
- Value-based pricing: Anchor the price to the clinical and economic value delivered over the current standard of care. Quantify avoided hospitalizations, reduced downstream procedures, improved survival, or superior tolerability to establish an upper bound.
- Cost-plus and return-on-investment floors: Check manufacturing cost of goods sold, distribution expenses, and the net revenue required to pay back remaining clinical trial and commercial launch investments.
- International reference pricing: Outside the US, national health authorities often cap reimbursement by referencing prices in peer countries or evaluating cost-effectiveness thresholds. Launching too low in one reference market can compress prices across other regions.
- Formularies, PBMs, and tier placement: In the US commercial market, insurers and pharmacy benefit managers (PBMs) place drugs onto formulary tiers. Low-copay preferred tiers drive rapid patient uptake, while non-preferred brand or specialty co-insurance tiers raise patient out-of-pocket costs and increase prescription abandonment.
- Utilization management and gross-to-net rebates: Payers restrict high-cost drugs using prior authorization forms and step edits (requiring patients to try a cheaper generic first). Manufacturers often concede rebates off the wholesale list price to win preferred tier placement without step edits, so always base your revenue math on net price rather than list price.
Worked example: Biopharma commercial sizing and break-even case
Life sciences cases often push beyond top-down revenue into clinical eligibility, manufacturing cost per patient, and upfront R&D payback. Below is an original worked case written by our team. The client and numbers are invented for practice.
Prompt: Your client, OncoVax Bio, is a clinical-stage biotech developing OV-101, a one-time autologous cell therapy for metastatic melanoma patients in the US who failed prior checkpoint inhibitor therapy. Management expects to spend $180 million in remaining clinical and manufacturing setup costs to reach approval. Should OncoVax fund the trial on its own if management requires cumulative gross profit to cover the $180 million investment within 3 years of launch?
Step 1: Clarify and structure. You confirm that OV-101 is a single-administration therapy, that the US is the only market in scope, and that operating overhead outside manufacturing is excluded for this screen. You organize four branches: eligible annual US patient volume, net price per treated patient after rebates, manufacturing cost per billed patient, and 3-year cumulative gross profit versus the $180 million hurdle.
Step 2: Patient funnel math (when you ask for epidemiology and adoption data, the interviewer shares the figures below). Walk through the funnel step by step with units:
- Annual US metastatic melanoma cases: 10,000 patients per year.
- Share treated with first-line immune checkpoint inhibitors: 80%, which gives 8,000 patients (10,000 times 0.80).
- Share refractory or relapsed after checkpoint therapy: 50% of those treated, which gives 4,000 clinically eligible patients per year (8,000 times 0.50).
- Share treated at certified academic cell-therapy centers able to harvest and infuse cells: 50%, leaving 2,000 addressable patients per year (4,000 times 0.50).
- Expected OV-101 market share over the first 3 years: 15% in Year 1 (300 patients), 25% in Year 2 (500 patients), and 30% in Year 3 (600 patients), for a 3-year total of 1,400 billed patients (300 + 500 + 600).
Worked example part 2: Pricing, CDMO unit economics, and synthesis
Step 3: Unit economics and gross profit math. You ask about pricing, payer rebates, and manufacturing costs. The interviewer tells you the wholesale list price is $250,000 per one-time infusion, average payer rebates and hospital discounts reduce list price by 20% to reach net revenue, and the contract manufacturer (CDMO) charges $81,000 per initiated patient batch. However, 10% of initiated batches fail potency release testing and must be absorbed by OncoVax without billing the payer.
Watch that batch-failure rate carefully. Here is the clean step-by-step arithmetic our team recommends saying out loud:
First, net revenue per billed patient is $250,000 times (1 minus 0.20) = $200,000. Second, because 10% of initiated batches fail release testing, only 90% (0.90) of initiated batches yield a billable infusion. Dividing the $81,000 batch cost by 0.90 gives an effective manufacturing cost of $90,000 per billed patient (every 10 batches cost $810,000 and treat 9 billed patients). Gross profit per billed patient is $200,000 minus $90,000 = $110,000.
Now multiply across the 3-year patient total: 1,400 billed patients times $110,000 gross profit per patient = $154,000,000 ($154 million) in cumulative 3-year gross profit. Against the $180 million upfront cost, OncoVax falls short by $26 million at the end of Year 3, though it reaches payback early in Year 4 if Year 3 volume holds steady at 600 patients ($66 million annual gross profit).
Step 4: Qualitative probe and synthesis. Interviewers frequently follow the math with a qualitative question, such as what you would ask key opinion leaders (oncologists) to test Year 2 and Year 3 adoption, or how OncoVax could close the $26 million gap. Strong ideas include co-developing with a larger pharma partner to share the $180 million trial cost, improving cell-culture yields to cut the 10% batch failure rate, or expanding referral networks into certified centers.
Model recommendation (our team's example): OncoVax should not self-fund OV-101 under the standalone baseline plan, because cumulative 3-year gross profit reaches $154 million, which is $26 million below the $180 million 3-year payback hurdle. However, the therapy generates $66 million in annual gross profit by Year 3 and pays back early in Year 4. I recommend pursuing two immediate options before shelving the asset: negotiate a co-development partnership that offsets at least $26 million of upfront trial spend, or validate with clinical investigators whether community-to-academic referral pathways can add roughly 240 cumulative patients ($26.4 million in gross profit) across Years 2 and 3.
Reading exhibits and handling unexpected prompts
Case exhibits test whether you extract only what answers the client's question instead of reading every axis label aloud. Take a quiet moment to note observations and spot trends that are not immediately obvious. As BCG's 45-minute, 23-question online practice case booklet illustrates, case data drills reward quantitative precision, such as remembering that 10% annual growth over 4 years compounds to 46% rather than 40%.
Practice reading the three exhibit formats that show up regularly in biopharma strategy cases, along with unexpected qualitative prompts:
- Kaplan-Meier survival curves: Check the vertical axis (percentage of patients alive or progression-free) against time on the horizontal axis. Trace across from the halfway mark on the vertical axis to compare median progression-free survival or median overall survival between the drug arm and the control arm, and check whether the curves separate early and stay apart or converge later.
- Clinical trial efficacy and safety tables: Never pick a winner on efficacy alone. Compare competing therapies side by side across response rates, severe adverse event rates, dosing frequency (oral daily pill versus hospital infusion), and whether trial populations had matching baseline disease severity.
- Patient funnels and gross-to-net waterfalls: Verify the units at each step before multiplying. Distinguish unique patients from prescriptions, vials, or treatment cycles, and check where the biggest drop-off occurs, whether at diagnosis, biomarker testing, payer prior authorization, or rebate discounts.
- Physician interview design and out-of-industry cases: If asked what questions you would pose to a prescribing specialist, group them into clinical efficacy, safety management, clinic workflow, and patient out-of-pocket coverage. If an interviewer gives an out-of-industry prompt, such as pricing a new transportation service, apply the exact same logic: customer value created, competing alternatives, willingness to pay, and unit cost floor.
Behavioral questions for undergrads and PhD or MD candidates
Do not spend all of your preparation hours on cases and neglect the fit interview. Consulting interviewers evaluate your answers against core qualities such as integrity, intellectual curiosity, creative thinking, collaborative mindset, and drive, and check whether you connect your past experiences to the daily demands of client work.
When telling behavioral stories, choose experiences that genuinely mattered to you. Focus on your specific individual role rather than saying 'we', and lead with your reasoning so the conversation feels natural rather than scripted.
If you are applying with an Advanced Professional Degree, which McKinsey's APD page defines as postdocs or candidates working toward a PhD, MD (including medical interns, residents, and fellows), JD, PharmD, Nursing, or qualifying non-MBA Masters degree (with at least four years between undergraduate and graduate completion), prepare specifically for questions about moving from academic research into team consulting. Be ready to explain why you want commercial strategy over bench science, how you decide with incomplete data, and how you work under a manager who is younger or does not hold a doctorate.
Build a compact bank of five personal stories covering leadership, resolving team conflict, recovering from a setback, persuading a skeptical stakeholder, and why life sciences consulting fits your goals.
A two-week preparation plan before your Putnam interview
Consistent out-loud practice beats passive reading. Keep consulting integrity rules in mind when using artificial intelligence: using AI beforehand to polish your resume, explain concepts or frameworks, and practice interview questions is encouraged, while using AI to generate real-time answers during an interview or assessment is not allowed.
Use this 14-day checklist written by our team to get ready on a focused schedule:
Practice a case free, no sign-up, whenever you are ready to test yourself.
- Days 1 to 3 (Custom structuring): Practice building three-to-four-branch structures out loud within two minutes across biopharma market sizing, drug pricing, product launch, and loss-of-exclusivity prompts.
- Practice summarizing survival curves and clinical comparison tables in two crisp sentences.
- Days 7 to 10 (Full candidate-led mocks): Complete one full 30-to-35-minute candidate-led case out loud each day. Practice stating a hypothesis, asking for specific data to test it, and proposing the next branch yourself.
- Days 11 to 13 (Behavioral stories and KOL drills): Rehearse your 'Why life sciences consulting' pitch and five behavioral stories focused on your individual reasoning. Practice designing a 4-question physician interview guide on the spot.
- Day 14 (Light review and virtual setup): Test your camera and audio with virtual backgrounds and AI note-takers turned off, set out blank scratch paper, pens, water, and your charger, and write down three thoughtful questions for your interviewers.
From BCG Careers, Consulting Case Study Interview Preparation, BCG Careers, Consulting Interview Process, BCG, Online Case Practice Booklet, McKinsey & Company, Interviewing at McKinsey, McKinsey & Company, Beautify Practice Case and McKinsey & Company, Advanced Professional Degree Candidates.
1 practice question and sample answer
Say your answer out loud first, then read the sample answer.
Practice question
Tell me about a time you worked under someone with less technical or academic experience than you, or had to translate complex scientific data for a non-specialist decision-maker.
Sample answer. Example answer written by our team. The applicant is invented. During the fourth year of my immunology PhD, I joined a university technology-transfer team to evaluate whether our lab's novel antibody assay could be licensed to diagnostic companies. Our project lead was a first-year MBA fellow who had no wet-lab background and was four years younger than me. Early on, I drafted a six-page technical summary focused on binding affinity curves, and she pushed back, telling me hospital buyers only cared about turnaround time and cost per test. Instead of defending the science, I asked her to walk me through how diagnostic purchasing committees score new assays. I realized my technical metrics did not answer the commercial question. I rebuilt my analysis around three numbers a hospital lab director could compare: technician minutes saved, reagent cost per run, and false-negative rate against the current standard. I then called four clinical lab directors with her to test our pricing assumptions. Two diagnostic firms entered licensing talks that semester, and I learned that deep data only creates impact when framed around the decision-maker's constraints.
It directly addresses the PhD-to-consulting transition probe without sounding defensive. The speaker owns an initial misstep, shows respect for a younger non-scientist manager, explains the reasoning behind changing the analysis, and ties technical lab data to commercial healthcare decisions.
Practice the case interview, out loud
Soreno's AI interviewer runs a full case one question at a time, checks your math and scores your structure, any time you have 30 minutes.
Questions people ask
What happens during a life sciences consulting case interview?
You are presented with a realistic business challenge and work through it step by step. You structure your approach, ask clarifying questions, analyze clinical or commercial data, perform quick calculations on paper, and recommend a clear course of action.
Is there only one right answer in a consulting case interview?
No. Case study interviews do not always have a single right answer. Interviewers focus on how you structure ambiguous problems, test assumptions, and back your reasoning with data.
Do I need a PhD or biology degree to pass a life sciences case interview?
No. Consulting firms hire problem-solvers from a wide range of undergraduate and advanced degree disciplines, evaluating critical thinking, structured logic, and clear communication rather than memorized medical facts.
Are calculators or AI tools allowed during virtual case interviews?
No. Calculators and real-time AI assistants or note-taking tools are not allowed during live consulting interviews, though using AI beforehand to practice questions and review concepts is encouraged.
Should I memorize standard case frameworks for Putnam Associates?
No. Interviewers look for candidates who listen carefully and build problem-specific structures that fit the client's exact clinical and commercial situation rather than reciting standard frameworks.
More guides
- Environmental Consulting Interview Questions and Answers
- McKinsey Acceptance Rate: Official Hiring Process & Stages
- Risk Consulting Interview Questions and Answers (2026)
- Consulting Presentation Slides: Structure, Charts & Build
- FTI Consulting Salary: Filings, Benchmarks & Pay (2026)
- Management Consulting Slide Deck: Structure and Guide
- CaseBasix Alternatives for Case Interview Prep (2026)
- Consulting Firm Hierarchy: Ranks at McKinsey, BCG and Bain
- Consulting Strategy Group: Services, Pay, and Vetting
- Deloitte Discovery Intern: How to Apply and Interview
- KPMG Verbal Reasoning Test: Format, Example and Prep
- Marketing and Strategy Consulting Firms Guide (2026)